Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Sarcoma 8Melanoma 3Hemangiosarcoma 3Breast Neoplasms 3Prostatic Neoplasms 2Osteosarcoma 2Neoplasms 2Leiomyosarcoma 2Carcinosarcoma 2Carcinoma, Endometrioid 2Vascular Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Tertiary Lymphoid Structures 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Liposarcoma 1Kidney Neoplasms 1Histiocytoma, Malignant Fibrous 1Hemangioendothelioma, Epithelioid 1

Interventions

Cyclophosphamide 76fludarabine phosphate 42Filgrastim 38Peripheral Blood Stem Cell Transplantation 35Radiotherapy 33Cyclosporine 32Busulfan 32Mycophenolic Acid 30Etoposide 30Antilymphocyte Serum 28Whole-Body Irradiation 26Methotrexate 25Rituximab 22Melphalan 21Methylprednisolone 20Vincristine 17Tacrolimus 17Cytarabine 17Cord Blood Stem Cell Transplantation 17Doxorubicin 16Prednisone 15Thiotepa 10Granulocyte Colony-Stimulating Factor 9Carboplatin 8Leucovorin 7fludarabine 6aldesleukin 6Ifosfamide 6sargramostim 5Sirolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dendritic Cell Sarcoma, Interdigitating × durvalumab × Sarcoma × Clear all
NCT03003520 2023-05-22

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Celgene

Phase 2 Completed
46 enrolled 20 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡